

Pei Hu

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6093569/pei-hu-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

88

papers

578

citations

12

h-index

19

g-index

98

ext. papers

739

ext. citations

3.7

avg, IF

3.64

L-index

#	Paper	IF	Citations
88	AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 2586-2597	6.1	56
87	First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 968-977	8.9	39
86	Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers. <i>Journal of Clinical Pharmacology</i> , 2009 , 49, 39-49	2.9	38
85	Simultaneous quantitative determination of olmesartan and hydrochlorothiazide in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010 , 878, 743-8	3.2	32
84	Quantitative determination of icotinib in human plasma and urine using liquid chromatography coupled to tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009 , 877, 3781-6	3.2	27
83	Determination of phenylephrine in human plasma using ultra-performance liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013 , 915-916, 28-32	3.2	20
82	Single-dose and multiple-dose pharmacokinetics and safety of telbivudine after oral administration in healthy Chinese subjects. <i>Journal of Clinical Pharmacology</i> , 2006 , 46, 999-1007	2.9	19
81	Psychomotor Recovery Following Remimazolam-induced Sedation and the Effectiveness of Flumazenil as an Antidote. <i>Clinical Therapeutics</i> , 2020 , 42, 614-624	3.5	16
80	Development and validation of a UPLC-MS/MS method for quantification of osimertinib (AZD9291) and its metabolite AZ5104 in human plasma. <i>Biomedical Chromatography</i> , 2018 , 32, e4365	1.7	14
79	Development of an UPLC-MS/MS method for quantification of Avitinib (AC0010) and its five metabolites in human cerebrospinal fluid: Application to a study of the blood-brain barrier penetration rate of non-small cell lung cancer patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017 , 139, 205-214	3.5	13
78	Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects. <i>Clinical Therapeutics</i> , 2015 , 37, 1483-1492.e1	3.5	13
77	Penetration of the blood-brain barrier by avitinib and its control of intra/extra-cranial disease in non-small cell lung cancer harboring the T790M mutation. <i>Lung Cancer</i> , 2018 , 122, 1-6	5.9	13
76	Pharmacokinetics and Safety of Tedizolid after Single and Multiple Intravenous/Oral Sequential Administrations in Healthy Chinese Subjects. <i>Clinical Therapeutics</i> , 2016 , 38, 1869-79	3.5	12
75	Combining Bottom-Up and Top-Down Methods to Assess Ethnic Difference in Clearance: Bitopertin as an Example. <i>Clinical Pharmacokinetics</i> , 2016 , 55, 823-832	6.2	12
74	Evaluating a physiologically based pharmacokinetic model for predicting the pharmacokinetics of midazolam in Chinese after oral administration. <i>Acta Pharmacologica Sinica</i> , 2016 , 37, 276-84	8	12
73	Development and validation of a rapid and sensitive UPLC-MS/MS method for quantification of kukoamine B in human plasma: Application to a clinical pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017 , 132, 1-6	3.5	11
72	Metabolite characterization of a novel sedative drug, remimazolam in human plasma and urine using ultra high-performance liquid chromatography coupled with synapt high-definition mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017 , 137, 78-83	3.5	10

71	Pharmacokinetics, pharmacodynamics, short term efficacy and safety of RCT-18, a novel BLyS/APRIL fusion protein, in patients with rheumatoid arthritis. <i>British Journal of Clinical Pharmacology</i> , 2016 , 82, 41-52	3.8	10
70	Population Pharmacokinetic/Pharmacodynamic Model-Guided Dosing Optimization of a Novel Sedative HR7056 in Chinese Healthy Subjects. <i>Frontiers in Pharmacology</i> , 2018 , 9, 1316	5.6	10
69	Pharmacokinetics of Single Ascending Doses and Multiple Doses of 20(S)-Ginsenoside Rg3 in Chinese Healthy Volunteers. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2016 , 41, 845-853	2.7	9
68	Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphoma. <i>Frontiers in Pharmacology</i> , 2018 , 9, 991	5.6	9
67	Simultaneous determination of blonanserin and its four metabolites in human plasma using ultra-performance liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013 , 939, 59-66	3.2	8
66	Pharmacodynamics and pharmacokinetics of fluticasone furoate/vilanterol in healthy Chinese subjects. <i>Pharmacotherapy</i> , 2015 , 35, 586-99	5.8	8
65	Pharmacokinetics, Pharmacodynamics, Safety, and Clinical Activity of Multiple Doses of RCT-18 in Chinese Patients With Systemic Lupus Erythematosus. <i>Journal of Clinical Pharmacology</i> , 2016 , 56, 948-59 ^{2.9}		8
64	Pharmacokinetics and pharmacodynamics of intravenous ilaprazole in healthy subjects after single ascending doses. <i>Xenobiotica</i> , 2016 , 46, 1133-1141	2	7
63	Pharmacokinetics, pharmacodynamics, and tolerability of single ascending doses of RCT-18 in Chinese patients with rheumatoid arthritis. <i>Clinical Pharmacokinetics</i> , 2014 , 53, 1033-44	6.2	7
62	A unified strategy in selection of the best allometric scaling methods to predict human clearance based on drug disposition pathway. <i>Xenobiotica</i> , 2016 , 46, 1105-1111	2	7
61	Translational Modeling and Simulation in Supporting Early-Phase Clinical Development of New Drug: A Learn-Research-Confirm Process. <i>Clinical Pharmacokinetics</i> , 2017 , 56, 925-939	6.2	6
60	Simultaneous determination of a novel c-Met/AXL dual-target small-molecule inhibitor BPI-9016M and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry: Application in a pharmacokinetic study in Chinese advanced solid tumor patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017 , 1012, 1050-1059	3.2	6
59	An UPLC-MS/MS method to determine CT-707 and its two metabolites in plasma of ALK-positive advanced non-small cell lung cancer patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018 , 153, 1-8	3.5	6
58	Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics. <i>Clinical Pharmacokinetics</i> , 2018 , 57, 1307-1323	6.2	6
57	Validation and Application of an LC-MS-MS Method for the Determination of Ceftizoxime in Human Serum and Urine. <i>Journal of Chromatographic Science</i> , 2016 , 54, 713-9	1.4	6
56	Pharmacokinetics and safety of subcutaneous pasireotide and intramuscular pasireotide long-acting release in Chinese male healthy volunteers: a phase I, single-center, open-label, randomized study. <i>Clinical Therapeutics</i> , 2014 , 36, 1196-210	3.5	6
55	A population pharmacokinetic study to accelerate early phase clinical development for a novel drug, teriflunomide sodium, to treat systemic lupus erythematosus. <i>European Journal of Pharmaceutical Sciences</i> , 2019 , 136, 104942	5.1	5
54	Simultaneous determination of roflumilast and its metabolite in human plasma by LC-MS/MS: Application for a pharmacokinetic study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016 , 1029-1030, 60-67	3.2	5

53	Development and validation of a UPLC-MS/MS method for simultaneous determination of fotaliptin and its two major metabolites in human plasma and urine. <i>Bioanalysis</i> , 2017 , 9, 381-393	2.1	4
52	An LC-MS/MS method for quantification of AC0010, a novel mutant-selective epidermal growth factor receptor (EGFR) inhibitor, and its metabolites in human plasma and the application to a pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017 , 141, 9-18	3.5	4
51	Safety, Pharmacokinetics, and Pharmacogenetics of Single-Dose Teriflunomide Sodium and Leflunomide in Healthy Chinese Subjects. <i>Clinical Drug Investigation</i> , 2019 , 39, 643-651	3.2	4
50	Simultaneous determination of remimazolam and its carboxylic acid metabolite in human plasma using ultra-performance liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2015 , 976-977, 78-83	3.2	4
49	Odanacatib Pharmacokinetics Comparison Between Chinese and Non-Chinese Postmenopausal Women. <i>Clinical Pharmacology in Drug Development</i> , 2018 , 7, 744-750	2.3	4
48	Pharmacokinetics, Pharmacodynamics and Preliminary Observations for Clinical Activity and Safety of Multiple Doses of Human Mouse Chimeric Anti-CD22 Monoclonal Antibody (SM03) in Chinese Patients with Systemic Lupus Erythematosus. <i>Clinical Drug Investigation</i> , 2016 , 36, 889-902	3.2	4
47	Pharmacokinetic and Pharmacodynamic Properties of Cinacalcet (KRN1493) in Chinese Healthy Volunteers: A Randomized, Open-label, Single Ascending-dose and Multiple-dose, Parallel-group Study. <i>Clinical Therapeutics</i> , 2016 , 38, 348-57	3.5	4
46	Determination of a PDE4 inhibitor Hemay005 in human plasma and urine by UPLC-MS/MS and its application to a PK study. <i>Bioanalysis</i> , 2018 , 10, 863-875	2.1	4
45	Pharmacokinetics, safety and tolerability of single and multiple oral doses of aliskiren in healthy Chinese subjects: a randomized, single-blind, parallel-group, placebo-controlled study. <i>Clinical Drug Investigation</i> , 2010 , 30, 221-8	3.2	4
44	A high-performance liquid chromatography-tandem mass spectrometry method for simultaneous determination of imiglitin, its five metabolites and aloglitin in human plasma and urine and its application to a multiple-dose pharmacokinetic study. <i>Biomedical Chromatography</i> , 2018 , 32, e4324	1.7	4
43	Pharmacokinetics of LBPT and its primary metabolites, as well as tolerability in the first-in-human study. <i>European Journal of Pharmaceutical Sciences</i> , 2017 , 100, 87-93	5.1	3
42	First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2020 , 13, 6	22.4	3
41	Phase 1 study to investigate the pharmacokinetic properties of dacomitinib in healthy adult Chinese subjects genotyped for CYP2D6. <i>Xenobiotica</i> , 2018 , 48, 459-466	2	3
40	Pharmacokinetics of Rasagiline in Healthy Adult Chinese Volunteers with Various Genotypes: A Single-Center, Open-Label, Multiple-Dose Study. <i>Clinical Drug Investigation</i> , 2016 , 36, 369-76	3.2	3
39	LCMSMS Method to Simultaneously Determine Six Probe Drugs for CYP450 Isozymes in Human Liver Microsomes. <i>Chromatographia</i> , 2014 , 77, 913-922	2.1	3
38	Development of an LC-MS/MS method for quantifying two main metabolites of abivertinib in human plasma. <i>Biomedical Chromatography</i> , 2020 , 34, e4704	1.7	3
37	Pharmacokinetics of single- and multiple-dose roflumilast: an open-label, three-way crossover study in healthy Chinese volunteers. <i>Drug Design, Development and Therapy</i> , 2018 , 12, 4047-4057	4.4	3
36	Simultaneous determination of imiglitin and its three metabolites in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2015 , 1002, 300-12	3.2	2

35	Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN). <i>BMC Endocrine Disorders</i> , 2020 , 20, 57	3.3	2
34	Translational prediction of first-in-human pharmacokinetics and pharmacodynamics of janagliflozin, a selective SGLT2 inhibitor, using allometric scaling, dedrick and PK/PD modeling methods. <i>European Journal of Pharmaceutical Sciences</i> , 2020 , 147, 105281	5.1	2
33	A validated UPLC-MS/MS method for the quantitation of an unstable peptide, monocyte locomotion inhibitory factor (MLIF) in human plasma and its application to a pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018 , 157, 75-83	3.5	2
32	A single and multiple dose study to investigate the pharmacokinetics of a prolonged release formulation of ropinirole in healthy Chinese subjects. <i>Clinical Pharmacology in Drug Development</i> , 2014 , 3, 84-92	2.3	2
31	Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BLYS/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis. <i>European Journal of Pharmaceutical Sciences</i> , 2021 , 159, 105704	5.1	2
30	Pharmacokinetics, Pharmacodynamics and Safety of Multiple-Infusion Ilaprazole in Healthy Chinese Subjects. <i>Clinical Drug Investigation</i> , 2016 , 36, 463-70	3.2	2
29	Application of a physiologically based pharmacokinetic model for the evaluation of single-point plasma phenotyping method of CYP2D6. <i>European Journal of Pharmaceutical Sciences</i> , 2016 , 92, 131-6	5.1	2
28	Development of a simple HPLC-MS/MS method to simultaneously determine teriflunomide and its metabolite in human plasma and urine: Application to clinical pharmacokinetic study of teriflunomide sodium and leflunomide. <i>Biomedical Chromatography</i> , 2019 , 33, e4420	1.7	2
27	Development of an HPLC-MS/MS method to determine janagliflozin in human plasma and urine: application in clinical study. <i>Bioanalysis</i> , 2018 , 10, 1439-1454	2.1	2
26	An Open-label, Single-dose, Pharmacokinetic Study of Factor VIII Activity After Administration of Moroctocog Alfa (AF-CC) in Male Chinese Patients With Hemophilia A. <i>Clinical Therapeutics</i> , 2017 , 39, 1313-1319	3.5	1
25	Simultaneous determination of TPN729 and its five metabolites in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018 , 151, 91-105	3.5	1
24	Non-Compartmental Pharmacokinetics and Safety of Single-Dose Eldecacitol (ED-71) in Healthy Chinese Adult Males. <i>Clinical Drug Investigation</i> , 2018 , 38, 901-908	3.2	1
23	A UPLC-MS/MS method for quantification of 5 α -androst-3 β ,6 β -triol in human plasma: development, validation and its application in clinical pharmacokinetic study. <i>Bioanalysis</i> , 2017 , 9, 873-885 ²⁻¹	2.1	1
22	A single-dose study investigating the pharmacokinetics and pharmacodynamics of edoxaban at 30-90 mg in healthy Chinese volunteers. <i>Xenobiotica</i> , 2017 , 47, 592-599	2	1
21	First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, a Small-Molecule Factor XIa Inhibitor in Healthy Subjects.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 821363	5.6	1
20	First China Approved Rituximab Biosimilar HLX01: Pharmacokinetics, Safety and Efficacy Comparison to Reference Rituximab in the Phase 3 Diffuse Large B-Cell Lymphoma Study. <i>Blood</i> , 2019 , 134, 2878-2878	2.2	1
19	A novel third generation EGFR tyrosine kinase inhibitor Abivertinib for EGFR T790M mutant Non-Small Cell Lung Cancer: a multicenter phase1/2 study. <i>Clinical Cancer Research</i> , 2021 ,	12.9	1
18	Simultaneous determination of FLZ and its metabolite (M1) in human plasma and urine by UHPLC-MS/MS: Application to a pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019 , 164, 32-40	3.5	1

17	Simultaneous determination of morphine-6-d-glucuronide, morphine-3-d-glucuronide and morphine in human plasma and urine by ultra-performance liquid chromatography-tandem mass spectrometry: Application to M6G injection pharmacokinetic study. <i>Biomedical Chromatography</i> , 2018 , 32, e4066	1.7	1
16	An ultra HPLC-MS/MS method for quantification of hypidone hydrochloride (YL-0919) and application to a pharmacokinetic study. <i>Bioanalysis</i> , 2019 , 11, 1243-1254	2.1	0
15	A UHPLC-MS/MS method to determine FLZ major active metabolites in human plasma: application to a pharmacokinetic study. <i>Bioanalysis</i> , 2020 , 12, 583-596	2.1	0
14	Reduced Effectiveness and Comparable Safety in Biweekly Weekly PEGylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency: A Phase IV Non-Inferiority Threshold Targeted Trial.. <i>Frontiers in Endocrinology</i> , 2021 , 12, 779365	5.7	0
13	Exposure-Response Modeling to Support Dosing Selection for Phase IIb Development of Kukoamine B in Sepsis Patients. <i>Frontiers in Pharmacology</i> , 2021 , 12, 645130	5.6	0
12	Ultra performance liquid chromatography tandem mass spectrometry assay for determination of kukoamine B in human blood and urine. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016 , 1031, 8-14	3.2	0
11	A high-performance liquid chromatography-tandem mass spectrometry method for the determination of lifrafenib, a novel RAF kinase and EGFR inhibitor, in human plasma and urine and its application in clinical pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019 , 166, 20-29	3.5	0
10	Modeling and Simulation to Support Phase Ib/Ila Dose Selection for WBP216, A Long Half-Life Fully Human Monoclonal Antibody Against Interleukin-6. <i>Frontiers in Pharmacology</i> , 2021 , 12, 617265	5.6	0
9	Metabolites characterization of a novel DPP-4 inhibitor, imigliptin in humans and rats using ultra-high performance liquid chromatography coupled with synapt high-resolution mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018 , 157, 189-200	3.5	0
8	CX1003 quantification by ultra-performance LC-MS/MS in human plasma and its application to a pharmacokinetic study in solid tumor patients. <i>Bioanalysis</i> , 2019 , 11, 1483-1493	2.1	
7	Determination of BPI15086 and its metabolite in human plasma by ultra-high performance liquid chromatography-MS/MS and its application to a pharmacokinetic study. <i>Bioanalysis</i> , 2019 , 11, 773-784	2.1	
6	UHPLC-MS/MS method to determine FP-208 in human plasma and its application to a pharmacokinetic study. <i>Bioanalysis</i> , 2020 , 12, 367-378	2.1	
5	BPI-9016M, a novel c-Met inhibitor, in pretreated advanced solid tumor: Results from a first-in-human, phase I, dose-escalation study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e21108-e21108	2.2	
4	Application of LC-MS/MS method for determination of dihydroartemisin in human plasma in a pharmacokinetic study. <i>Bioanalysis</i> , 2020 , 12, 1635-1646	2.1	
3	Pharmacokinetics and safety evaluation of oral Palonosetron in Chinese healthy volunteers: A phase 1, open-label, randomized, cross-over study. <i>European Journal of Pharmaceutical Sciences</i> , 2021 , 160, 105752	5.1	
2	Population Pharmacokinetic Analysis of Yimitasvir in Chinese Healthy Volunteers and Patients With Chronic Hepatitis C Virus Infection. <i>Frontiers in Pharmacology</i> , 2020 , 11, 617122	5.6	
1	A phase 1 pharmacokinetic study of oral NEPA, the fixed combination of netupitant and palonosetron, in Chinese healthy volunteers. <i>Cancer Chemotherapy and Pharmacology</i> , 2021 , 87, 387-396 ^{3.5}		